Pharmacological approach to diabetic macular edema

Ophthalmic Research
F BandelloM Battaglia Parodi

Abstract

Diabetic macular edema (DME) is a highly prevalent cause of vision loss and has a remarkable impact on public health, and on the quality of life of diabetic patients. Even though laser photocoagulation has been the standard of care for decades, a substantial group of patients are unresponsive and fail to improve after laser treatment. Recently, new pharmacological approaches based on the use of intravitreal drugs, such as corticosteroids and anti-vascular endothelial growth factor, have revolutionized the treatment of DME. The use of intravitreal drugs is supported by the improvement in visual acuity reported by several clinical trials and can limit the potentially destructive effects of the laser treatment. Encouraging results also emerged from studies evaluating the use of a combination therapy, or the association of intravitreal drugs and laser treatment. This review aims at providing a brief synopsis of the main investigations regarding the current pharmacological approach to DME.

Citations

Oct 27, 2016·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Anna BongDavid C Mansfield
Nov 6, 2015·International Ophthalmology·O H OnakpoyaO Laoye

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Archivos de la Sociedad Española de Oftalmología
F Cabrera, F Armadá
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Amol D Kulkarni, Michael S Ip
Journal of Ophthalmology
Dinah Zur, Anat Loewenstein
Developments in Ophthalmology
P IaconoFrancesco Bandello
© 2021 Meta ULC. All rights reserved